Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II studyJindong Sheng, Wenxin Liu, Wenhao Zhou et al.|Signal Transduction and Targeted Therapy|2025Cited by 15
Neoadjuvant tislelizumab plus chemotherapy among patients with locally advanced cervical cancer: A prospective, single-arm, phase II trialJindong Sheng, Ke Wang, Wenxin Liu et al.|Gynecologic Oncology|2024Cited by 0